CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...
Phase 1
Detroit, Michigan, United States and 20 other locations
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...
Phase 3
Detroit, Michigan, United States and 107 other locations
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...
Phase 4
Detroit, Michigan, United States and 36 other locations
This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...
Phase 4
Detroit, Michigan, United States and 35 other locations
for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS...
Phase 3
Detroit, Michigan, United States and 60 other locations
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥1...
Phase 3
Detroit, Michigan, United States and 312 other locations
) neo-antigen in subjects with relapsing multiple sclerosis (RMS).COVID-19 sub-study:The purpose of this research sub-study is to e...
Phase 3
Detroit, Michigan, United States and 301 other locations
This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple...
Phase 3
Detroit, Michigan, United States and 209 other locations
Clinical trials
Research sites
Resources
Legal